Susceptibility of Brucella melitensis to the new fluoroquinolone PD 131628: comparison with other drugs.
The antibacterial activity of PD 131628 was determined by the broth dilution method against 105 clinical isolates of Brucella melitensis. Fifty-two and ninety-nine percent of the isolates were inhibited by 0.06 and 0.12 microgram/ml of this quinolone, respectively. One strain which was resistant to 8 other fluoroquinolones, with a minimum inhibitory concentration (MIC) of > 4.0 micrograms/ml, did not show cross-resistance and had an MIC of 2.0 micrograms/ml. Of the 9 fluoroquinolones tested, PD 131628 was most inhibitory followed by CI-960. All the strains were susceptible to conventional drugs like gentamicin, rifampicin, tetracycline and trimethoprim-sulfamethoxazole, with MICs ranging between 0.12 and 1.0 microgram/ml. PD 131628 did not exhibit in vitro synergy with any of the conventional drugs.
Qadri
S M
SM
King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Ueno
Y
Y
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017347:Brucella melitensis / Q000187:drug effects*; D024841:Fluoroquinolones; D008826:Microbial Sensitivity Tests; D009287:Naphthyridines; D015363:Quinolones / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D015363:Quinolones; C068217:PD 131628; C057477:clinafloxacin